- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Guideline: Metformin Best to Control HbA1c
Metformin should be the first drug of choice in oral therapy for type 2 diabetics who don't respond to diet and lifestyle changes, according to a new guideline.
A second agent can be added if metformin monotherapy fails to control hyperglycemia, but there's insufficient evidence to recommend one secondary agent over another, Amir Qaseem, MD, PhD, director of clinical policy at the American College of Physicians, and colleagues wrote in the organization's new guideline for the management of type 2 diabetes, published in the Annals of Internal Medicine.
"We found that most diabetes medications reduced blood sugar levels to a similar degree," Qaseem said in a statement. "However, metformin is more effective compared to other type 2 diabetes drugs in reducing blood sugar levels when used alone and in combination with other drugs."
Read more at: http://tinyurl.com/7yy8ekp
Source: MedPage Today
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
